NOVADAQ presents at J.P. Morgan Healthcare Conference
Tuesday, January 13, 2015 11:30 am (8:30 am PST)
An explanation of the quarterly results may be interesting.
Seriously, let the lawsuits follow. We should have known something stunk when the CFO resigned. No credibility with the company IMO.
I dont think there is that much of a runway for growth beyond 2015's reduced outlook. I also think another cut to guidance is likely.
Sentiment: Strong Sell
Jay why do you say it is a joke? The technology is effective and proven. It is cost beneficial in that it not only provides guidance to surgeons in making decisions on treatment and surgeries but it saves repair and the subsequent legal costs. The $6.00 stock estimate is based on what? I see the price higher than would be demanded from the current revenue and market penetration, but this is a new technology / service and will need time to penetrate the medical community. I ask in all sincerity. I am an investor and am always open to views and insights other than mine for re-evaluation.
Thanks in advance
what a complete and utter joke. I have not covered a share despite the pain from mo mo longs trying to create a squeeze. This is a $6 stock.
Sentiment: Strong Sell
I think the 100 is now the last line of defense, currently at 14.11 not too much suffering if your still long.
If NVDQ reverses back up off the 100, It'll be good for a run as disoriented weak hands mill around the train station receding in the rear distance.
The surprise lower Q4 earnings according to Arun was due to the significant drop in capital sales from LifeCell. Now that this product has been brought back into the NVDQ fold, I expect there will be a ramp up time of a year or so. Remember the agreement was that no sales personnel would be taken by NVDQ for 1 year. This is a blow to the contacts established though will be transient in nature. He did say that the PINPOINT and LUNA sales for Q4 exceeded their expectations. If NVDQ received ~$125k of the ~$250k sale price from LifeCell, then there would have been at least 16 sales that were not made that were expected, perhaps even more if the PINPOINT and LUNA sales were greater than anticipated. I see this as a transient and not a change in the fundamentals for Novadaq. I expect the market to be shortsighted and the short sellers may be in charge, at least until tomorrows Analyst Day when Arun will have the opportunity to explain the strategic and tactical response and anticipated results.
Yesterday' price action across the market was very troubling, particularly in NVDQ.
Lightened up on a number of holdings.
Monday will tell if mr market falls down or headfakes.
Recent behavior is def frustrating/disturbing. Not a huge student of technicals, but after yrs above the 200-day MA - that bubble finally burst in Spring 2014 for the 1st time and the stock broke from $17 down to $10.50. Since that break in April '14 NVDQ has struggled to pop its head above the 200-day MA (only once for a few weeks in Dec '14 into the New Year). Even with the SPY/Lifecell win and addl rev as well as the Lifenet DermACELL JV seeling tissue into SPY mkts, seems to be a real 'show me/skeptical attitude' now about the story. Just have to be patient I guess about seeing what the mkt believes 45-55% y/y top-line is worth.
Arun has stated 3 metrics to judge the progress of the company~.
1. procedure growth
2. total revenues
3. gross margins
At this point, lacking analysts' reporting on "channel checks", or other anecdotal updates, we are all hostage to the presentations by the company, either via quarterly cc or healthcare conference webcasts...and that's the rub..in the interim it's all about non fundamentals, such as sentiment, emotion, short term trading, including shorting, global headlines and market noise..